Physician profile
Ayman Arouse
NPI 1114019304
$2,508.08
in general payments reported to CMS, 2019-2025
22 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $39.96 · 2021: $331 · 2022: $634 · 2023: $609 · 2024: $393 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $577.17 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $470.58 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $251.02 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $159.52 | 2019-2023 | Bexsero, Pediarix, Rotarix |
| Gm Pharmaceuticals, INC. | $143.43 | 2022 | |
| Cranial Technologies, INC | $140.06 | 2019-2024 | Doc Band |
| Tris Pharma INC | $135.43 | 2019-2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $97.97 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.11 | 2019-2021 | |
| Pfizer INC. | $86.08 | 2019-2024 | |
| Medline Industries LP | $59.70 | 2019 | |
| Acadia Pharmaceuticals INC | $56.68 | 2023-2024 | Daybue |
| Sanofi-Aventis U.S. LLC | $39.66 | 2024-2025 | |
| Sobi, INC | $32.18 | 2019-2021 | |
| Seqirus USA INC | $31.76 | 2022-2025 | Flucelvax |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $31.02 | 2019 | |
| Krystal Biotech INC | $23.55 | 2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $21.60 | 2023 | Ycanth |
| Cipher Pharmaceuticals US LLC | $21.08 | 2025 | Natroba, Spinosad |
| Sanofi Pasteur INC. | $16.55 | 2024 | |
| Collegium Pharmaceutical, INC. | $14.06 | 2025 | Jornay Pm |
| Mission Pharmacal Company | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Arouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.